Pharmapedia Pro
Back to News
Recall20 Nov 2026Source: FDA Safety Alerts

FDA Issues Early Alert on Recall of Heraeus Medevio Vascular Guidewires

The US FDA has released an early alert regarding a voluntary medical device recall initiated by Heraeus Medical Components (Heraeus Medevio) involving certain vascular guidewires. The affected products include specific lots of Navilyst, Spectrum, and Arrow Marked guidewires, which are indicated for percutaneous entry into peripheral vessels using the Seldinger technique.

The alert follows reports that the hydrophilic coating on these guidewires can swell unevenly when hydrated with saline, resulting in coating clumping, predominantly on the distal coil tip. This clumping increases the danger of coating flaking, displacement, or complete detachment into the patient's bloodstream, posing a risk of hydrophilic polymer embolization, vessel occlusion, tissue ischemia, infarction, and other thromboembolic complications.

The FDA advises facilities and distributors to immediately stop distributing and using the affected guidewire lots, check their distribution records, and quarantine any remaining stock. As of November 5, 2026, the manufacturer had not received reports of serious injuries or deaths related to this defect.

Key points

  • Heraeus Medevio recalled select lots of Navilyst, Spectrum, and Arrow Marked vascular guidewires.
  • Saline hydration may cause uneven swelling and clumping of the hydrophilic coating, mainly at the distal coil section.
  • Dislodged coating fragments entering the bloodstream can cause hydrophilic polymer embolization, thrombosis, or vascular occlusion.
  • Healthcare providers and supply managers are advised to immediately halt use and quarantine affected inventory.

What it means for you

Clinicians, interventional radiologists, and catheterisation laboratory personnel in Pakistan should inspect device supplies for the recalled Navilyst, Spectrum, and Arrow Marked guidewire models and quarantine affected units. Practitioners should refer to the Drug Regulatory Authority of Pakistan (DRAP) for local product status and regulatory advisories. Any suspected device malfunctions or embolic complications should be reported through standard pharmacovigilance and device vigilance channels.

Read the original announcement

Early Alert: Heraeus Medical Components Removes Vascular Guidewires

Summarised automatically from the official announcement. For educational purposes only — check the original source before making clinical decisions.